Cargando…

Mechanism of Anti-α-Synuclein Immunotherapy

Immunization therapy targeting α-synuclein has emerged as a promising approach for Parkinson’s disease and perhaps for other synucleinopathies. Several antibodies have shown therapeutic effects in mouse models of synucleinopathies and have alleviated the pathological and behavioral phenotypes of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jun Sung, Lee, Seung-Jae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Movement Disorders Society 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4734990/
https://www.ncbi.nlm.nih.gov/pubmed/26828212
http://dx.doi.org/10.14802/jmd.15059
_version_ 1782412999268499456
author Lee, Jun Sung
Lee, Seung-Jae
author_facet Lee, Jun Sung
Lee, Seung-Jae
author_sort Lee, Jun Sung
collection PubMed
description Immunization therapy targeting α-synuclein has emerged as a promising approach for Parkinson’s disease and perhaps for other synucleinopathies. Several antibodies have shown therapeutic effects in mouse models of synucleinopathies and have alleviated the pathological and behavioral phenotypes of these mice. The mechanisms through which the immunization therapy works were initially puzzling, especially given that α-synuclein is a typical cytosolic protein. Recent studies, however, suggested that extracellular α-synuclein is an important pathogenic entity, and hence, a target for immunotherapy. Here, we review the literature describing immunization therapy for synucleinopathies in mouse models and provide current thoughts on the potential mechanisms underlying the therapeutic effects of α-synuclein immunotherapy.
format Online
Article
Text
id pubmed-4734990
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher The Korean Movement Disorders Society
record_format MEDLINE/PubMed
spelling pubmed-47349902016-02-08 Mechanism of Anti-α-Synuclein Immunotherapy Lee, Jun Sung Lee, Seung-Jae J Mov Disord Review Article Immunization therapy targeting α-synuclein has emerged as a promising approach for Parkinson’s disease and perhaps for other synucleinopathies. Several antibodies have shown therapeutic effects in mouse models of synucleinopathies and have alleviated the pathological and behavioral phenotypes of these mice. The mechanisms through which the immunization therapy works were initially puzzling, especially given that α-synuclein is a typical cytosolic protein. Recent studies, however, suggested that extracellular α-synuclein is an important pathogenic entity, and hence, a target for immunotherapy. Here, we review the literature describing immunization therapy for synucleinopathies in mouse models and provide current thoughts on the potential mechanisms underlying the therapeutic effects of α-synuclein immunotherapy. The Korean Movement Disorders Society 2016-01 2016-01-25 /pmc/articles/PMC4734990/ /pubmed/26828212 http://dx.doi.org/10.14802/jmd.15059 Text en Copyright © 2016 The Korean Movement Disorder Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Lee, Jun Sung
Lee, Seung-Jae
Mechanism of Anti-α-Synuclein Immunotherapy
title Mechanism of Anti-α-Synuclein Immunotherapy
title_full Mechanism of Anti-α-Synuclein Immunotherapy
title_fullStr Mechanism of Anti-α-Synuclein Immunotherapy
title_full_unstemmed Mechanism of Anti-α-Synuclein Immunotherapy
title_short Mechanism of Anti-α-Synuclein Immunotherapy
title_sort mechanism of anti-α-synuclein immunotherapy
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4734990/
https://www.ncbi.nlm.nih.gov/pubmed/26828212
http://dx.doi.org/10.14802/jmd.15059
work_keys_str_mv AT leejunsung mechanismofantiasynucleinimmunotherapy
AT leeseungjae mechanismofantiasynucleinimmunotherapy